Australian Broker Call *Extra* Edition – Feb 05, 2026

Array
(
    [0] => Array
        (
            [0] => ((AIA))
            [1] => ((AIZ))
            [2] => ((BET))
            [3] => ((BPT))
            [4] => ((CIA))
            [5] => ((CMA))
            [6] => ((COL))
            [7] => ((WOW))
            [8] => ((COL))
            [9] => ((EDV))
            [10] => ((COV))
            [11] => ((DUG))
            [12] => ((DVP))
            [13] => ((DXB))
            [14] => ((EDV))
            [15] => ((WOW))
            [16] => ((COL))
            [17] => ((ELD))
            [18] => ((EMR))
            [19] => ((HRZ))
            [20] => ((ILU))
            [21] => ((IPD))
            [22] => ((JIN))
            [23] => ((KCN))
            [24] => ((KMD))
            [25] => ((LRK))
            [26] => ((LTR))
            [27] => ((NAB))
            [28] => ((WBC))
            [29] => ((CBA))
            [30] => ((ANZ))
            [31] => ((MQG))
            [32] => ((JDO))
            [33] => ((NEC))
            [34] => ((OBM))
            [35] => ((ORG))
            [36] => ((PLS))
            [37] => ((PXA))
            [38] => ((REG))
            [39] => ((RMD))
            [40] => ((RMD))
            [41] => ((TPW))
            [42] => ((BRG))
            [43] => ((SIG))
            [44] => ((WAF))
        )

    [1] => Array
        (
            [0] => AIA
            [1] => AIZ
            [2] => BET
            [3] => BPT
            [4] => CIA
            [5] => CMA
            [6] => COL
            [7] => WOW
            [8] => COL
            [9] => EDV
            [10] => COV
            [11] => DUG
            [12] => DVP
            [13] => DXB
            [14] => EDV
            [15] => WOW
            [16] => COL
            [17] => ELD
            [18] => EMR
            [19] => HRZ
            [20] => ILU
            [21] => IPD
            [22] => JIN
            [23] => KCN
            [24] => KMD
            [25] => LRK
            [26] => LTR
            [27] => NAB
            [28] => WBC
            [29] => CBA
            [30] => ANZ
            [31] => MQG
            [32] => JDO
            [33] => NEC
            [34] => OBM
            [35] => ORG
            [36] => PLS
            [37] => PXA
            [38] => REG
            [39] => RMD
            [40] => RMD
            [41] => TPW
            [42] => BRG
            [43] => SIG
            [44] => WAF
        )

)

This story features AUCKLAND INTERNATIONAL AIRPORT LIMITED, and other companies.
For more info SHARE ANALYSIS: AIA
The company is included in ASX200, ASX300 and ALL-ORDS

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.

One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.

Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.

Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.

The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.

The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.

COMPANIES DISCUSSED IN THIS ISSUE

Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)

AIA   AIZ   BET   BPT   CIA   CMA   COL   COV   DUG   DVP   DXB   EDV   ELD   EMR   HRZ   ILU   IPD   JIN   KCN   KMD   LRK   LTR   NAB   NEC   OBM   ORG   PLS   PXA   REG   RMD (2)   TPW   WAF  

AIA    AUCKLAND INTERNATIONAL AIRPORT LIMITED

Infrastructure & Utilities – Overnight Price: $7.16

Jarden rates ((AIA)) as Neutral (3) –

At the upcoming 1H26 results, Jarden expects Auckland International Airport to report 1H26 net profit of NZ$155m, noting its full FY26 forecast of NZ$304m sits mid-range of guidance.

Revenue and EBITDA are expected to be evenly split across 1H/2H, while net profit is modestly 2H-weighted due to rising depreciation and interest costs.

The broker sees passenger volumes as achievable based on forward schedules, and sees risks around volumes recovery rate, costs and regulation.

Neutral rating and NZ$7.93 target are unchanged.

This report was published on January 30, 2026.

Current Price is $7.16. Target price not assessed.
Current consensus price target is $7.13, suggesting downside of -1.2%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 11.96 cents and EPS of 15.56 cents.
At the last closing share price the estimated dividend yield is 1.67%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 46.02.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 15.7, implying annual growth of N/A.
Current consensus DPS estimate is 11.2, implying a prospective dividend yield of 1.6%.
Current consensus EPS estimate suggests the PER is 46.0.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 12.59 cents and EPS of 18.08 cents.
At the last closing share price the estimated dividend yield is 1.76%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 39.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 16.5, implying annual growth of 5.1%.
Current consensus DPS estimate is 12.0, implying a prospective dividend yield of 1.7%.
Current consensus EPS estimate suggests the PER is 43.8.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

AIZ    AIR NEW ZEALAND LIMITED

Transportation & Logistics – Overnight Price: $0.50

Jarden rates ((AIZ)) as Underweight (4) –

Jarden’s forecast for Air New Zealand’s 1H26 net loss of -NZ$43m sits around the midpoint of guidance. The broker notes underlying profitability remains weak even on a full-fleet basis, highlighting the impact of higher competition, cost pressures and soft demand.

With domestic yields having peaked and competitor capacity returning across international and domestic markets, the broker sees growing pressure on pricing and margins.

Underweight rating and NZ55c target. The broker flags downside risks to its forecasts, given structural opex increases and limited scope for yield recovery.

This report was published on January 30, 2026.

Current Price is $0.50. Target price not assessed.
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 2.25 cents and EPS of 0.63 cents.
At the last closing share price the estimated dividend yield is 4.50%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 79.37.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 2.25 cents and EPS of 2.79 cents.
At the last closing share price the estimated dividend yield is 4.50%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.93.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

BET    BETMAKERS TECHNOLOGY GROUP LIMITED

Gaming – Overnight Price: $0.21

Canaccord Genuity rates ((BET)) as Speculative Buy (1) –

Canaccord Genuity notes 2Q26 confirmed Betmakers Technology’s operational turnaround, with revenue growth of 14% ahead of expectations, driven by improving underlying demand and recent customer wins.

Adjusted earnings (EBITDA) of $2.7m was slightly below forecast due to lower gross margins and working capital headwinds, though operating cash flow turned positive and the broker sees a sustainable free cash flow profile emerging.

Management expects gross margins to continue improving toward its 70% long-term target, while contributions from Crown, Penn Entertainment and Stake are forecast to lift earnings materially in 2H26.

Speculative Buy maintained, with unchanged target of 22c.

This report was published on January 29, 2026.

Target price is $0.22 Current Price is $0.21 Difference: $0.01
If BET meets the Canaccord Genuity target it will return approximately 5% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.37 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 56.76.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

BPT    BEACH ENERGY LIMITED

Crude Oil – Overnight Price: $1.25

Jarden rates ((BPT)) as Sell (5) –

Jarden will look for clarity on the future pace of the ramp up of Waitsia and a comprehensive update to address key uncertainties when Beach Energy dellivers its interim results on February 5.

The market is expected to look for clarity on future growth strategy and a potential cut in dividends to help fund this growth. Sell rating and $0.90 target unchanged.

This report was published on February 2, 2026.

Target price is $0.90 Current Price is $1.25 Difference: minus $0.35 (current price is over target).
If BPT meets the Jarden target it will return approximately minus 28% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $1.07, suggesting downside of -14.4%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 3.50 cents and EPS of 13.60 cents.
At the last closing share price the estimated dividend yield is 2.80%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.19.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 16.0, implying annual growth of N/A.
Current consensus DPS estimate is 4.0, implying a prospective dividend yield of 3.2%.
Current consensus EPS estimate suggests the PER is 7.8.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 4.50 cents and EPS of 17.90 cents.
At the last closing share price the estimated dividend yield is 3.60%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 6.98.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 18.0, implying annual growth of 12.5%.
Current consensus DPS estimate is 6.3, implying a prospective dividend yield of 5.0%.
Current consensus EPS estimate suggests the PER is 6.9.

Market Sentiment: -0.4
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

CIA    CHAMPION IRON LIMITED

Iron Ore – Overnight Price: $5.75

Jarden rates ((CIA)) as Overweight (2) –

Jarden assesses Champion Iron’s December quarter update as solid, with production and sales beating expectations. Site inventories declined toward target, and temporary port stockpiling is expected to unwind as DRPF (Direct Reduction Pellet Feed) ramps.

Costs materially outperformed due to lower subcontractor costs and no major maintenance, but the broker expects it to rise in the March quarter before normalising.

DRPF remains on track for on-time, on-budget commissioning in April, the broker highlights, while the Rana Gruber acquisition adds strategic diversification and European market exposure.

Overweight rating and $5.70 target are unchanged. Champion is the broker’s preferred stock among iron ore producers.

This report was published on January 31, 2026.

Target price is $5.70 Current Price is $5.75 Difference: minus $0.05 (current price is over target).
If CIA meets the Jarden target it will return approximately minus 1% (excluding dividends, fees and charges – negative figures indicate an expected loss).
The company’s fiscal year ends in March.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 22.00 cents and EPS of 41.69 cents.
At the last closing share price the estimated dividend yield is 3.83%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.79.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 13.00 cents and EPS of 42.47 cents.
At the last closing share price the estimated dividend yield is 2.26%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.54.

This company reports in CAD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

CMA    CARMA LIMITED

Automobiles & Components – Overnight Price: $1.76

Canaccord Genuity rates ((CMA)) as Buy (1) –

Momentum continued through the 2Q26 with Carma delivering in-line results as revenue rose 48% y/y to $27m and first-half revenue of around $51m met expectations, notes Canaccord Genuity.

Retail revenue increased 12% q/q while wholesale accelerated 35% q/q, lifting gross profit 88% y/y to $2.5m, with margins steady at 9% and scope for expansion as reconditioning utilisation improves.

Operating cash outflow of -$14m in 1H26, excluding IPO costs, left cash of $58m and total liquidity of circa $78m including the bailment facility, which the broker views as adequate to support growth.

Buy and the $3.50 target are retained, with forecasts unchanged.

This report was published on January 30, 2026.

Target price is $3.50 Current Price is $1.76 Difference: $1.74
If CMA meets the Canaccord Genuity target it will return approximately 99% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 25.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 6.98.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 25.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 6.88.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

COL    COLES GROUP LIMITED

Food, Beverages & Tobacco – Overnight Price: $21.69

Jarden rates ((COL)) as Neutral (3) –

Jarden’s FMCG survey results were most positive for Woolworths Group ((WOW)) but Coles Group ((COL)) is still widely expected to outperform in 2026, a view the broker sees as increasingly at risk.

Overall sentiment was more pessimistic than expected, reflecting regulatory risk, easing inflation and more value-conscious consumers amid heightened competition.

The broker favours FMCG and category leaders, while flagging pricing risks for Coles and Endeavour Group ((EDV)) in 2H26. 

Neutral rating for Coles. Target price $23.

This report was published on January 30, 2026.

Target price is $23.00 Current Price is $21.69 Difference: $1.31
If COL meets the Jarden target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $24.67, suggesting upside of 13.9%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 78.00 cents and EPS of 93.90 cents.
At the last closing share price the estimated dividend yield is 3.60%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.10.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 94.9, implying annual growth of 17.5%.
Current consensus DPS estimate is 79.2, implying a prospective dividend yield of 3.7%.
Current consensus EPS estimate suggests the PER is 22.8.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 85.00 cents and EPS of 102.80 cents.
At the last closing share price the estimated dividend yield is 3.92%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 21.10.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 104.1, implying annual growth of 9.7%.
Current consensus DPS estimate is 87.7, implying a prospective dividend yield of 4.0%.
Current consensus EPS estimate suggests the PER is 20.8.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

COV    CLEO DIAGNOSTICS LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.63

Petra Capital rates ((COV)) as Buy (1) –

Petra Capital observes Cleo Diagnostics has just filed its 4C and quarterly activities report, which offered no surprises to the analyst.

A $5m placement and R&D tax incentive of $1.7m boosted cash to $9.6m at the end of December from $4.6m at the end of September. Net cash inflow of $176k, combined with the $1.7m R&D rebate, while gross spend was -$1.5m.

Management highlighted subject recruitments are expected to reach 500 in the US triage clinical trial soon. Cleo is also in discussions with its manufacturing partner, and an agreement is anticipated in 1Q2026.

Petra Capital retains a Buy rating and $1.15 target. The broker’s earnings forecasts are being reviewed.

This report was published on February 1, 2026.

Target price is $1.15 Current Price is $0.63 Difference: $0.52
If COV meets the Petra Capital target it will return approximately 83% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Petra Capital forecasts a full year FY26 dividend of 0.00 cents.

Forecast for FY27:

Petra Capital forecasts a full year FY27 dividend of 0.00 cents.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

DUG    DUG TECHNOLOGY LIMITED

Cloud services – Overnight Price: $1.79

Canaccord Genuity rates ((DUG)) as Buy (1) –

Dug Technology’s share price weakness following the quarterly update combined with the sell-off over the past week offers a compelling opportunity, in Canaccord Genuity’s view.

With the launch of Elastic MP-FWI and recent expansion into Brazil and the Middle East, Dug now has the most comprehensive product and geographic footprint in its history, the broker notes, positioning it for sustained Services awards over the next 12–24 months.

With the upcoming first half result likely to demonstrate growing contract momentum and margin leverage, Canaccord believes now is the time to revisit the name. Buy and $2.90 target retained.

This report was published on February 2, 2026.

Target price is $2.90 Current Price is $1.79 Difference: $1.11
If DUG meets the Canaccord Genuity target it will return approximately 62% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 3.08 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 58.17.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 7.69 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 23.27.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

DVP    DEVELOP GLOBAL LIMITED

Industrial Metals – Overnight Price: $5.49

Canaccord Genuity rates ((DVP)) as Upgrade to Speculative Buy from Hold (1) –

Commissioning at Woodlawn continues, with Develop Global reiterating it is on track to reach nameplate capacity of 850ktpa this quarter. Dec Q Revenue of $55.5m was in line with Canaccord Genuity and steady quarter on quarter.

During the quarter, Develop Global was awarded a five-year, $200m underground development contract to establish the Waihi North Gold Project owned by OceanaGold. 

Management highlighted it was assessing and progressing a substantial volume of tenders, reflecting favourable market conditions. Target rises to $5.70 from $5.05, upgrade to Speculative Buy from Hold.

This report was published on February 2, 2026.

Target price is $5.70 Current Price is $5.49 Difference: $0.21
If DVP meets the Canaccord Genuity target it will return approximately 4% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 17.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 32.29.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 66.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.32.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

DXB    DIMERIX LIMITED

Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $0.53

Petra Capital rates ((DXB)) as Buy (1) –

Petra Capital notes Dimerix’s 2Q26 4C showed cash of $38.5m, with operating cash outflow easing to $11.1m q/q but still above expectations, partly reflecting the absence of a circa $2m R&D rebate and residual one-off costs.

The broker expects burn to moderate now that recruitment for the ACTION 3 FSGS trial is complete and highlights Dimerix remains well funded to progress the trial and commercial readiness.

Focus remains on upcoming FDA feedback, which will determine the timing of a blinded statistical powering analysis and whether a 12-month accelerated approval pathway for DMX-200 remains viable.

Petra Capital retains a Buy rating and $1.46 target, with forecasts under review.

This report was published on February 1, 2026.

Target price is $1.46 Current Price is $0.53 Difference: $0.93
If DXB meets the Petra Capital target it will return approximately 175% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Petra Capital forecasts a full year FY26 dividend of 0.00 cents.

Forecast for FY27:

Petra Capital forecasts a full year FY27 dividend of 0.00 cents.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

EDV    ENDEAVOUR GROUP LIMITED

Food, Beverages & Tobacco – Overnight Price: $3.66

Jarden rates ((EDV)) as Underweight (4) –

Jarden’s FMCG survey results were most positive for Woolworths Group ((WOW)) but Coles Group ((COL)) is still widely expected to outperform in 2026, a view the broker sees as increasingly at risk.

Overall sentiment was more pessimistic than expected, reflecting regulatory risk, easing inflation and more value-conscious consumers amid heightened competition.

The broker favours FMCG and category leaders, while flagging pricing risks for Coles and Endeavour Group in 2H26. 

Underweight rating for Endeavour. Target price $3.20.

This report was published on January 30, 2026.

Target price is $3.20 Current Price is $3.66 Difference: minus $0.46 (current price is over target).
If EDV meets the Jarden target it will return approximately minus 13% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $3.72, suggesting upside of 2.0%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 EPS of 21.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 17.10.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 22.1, implying annual growth of -7.1%.
Current consensus DPS estimate is 16.4, implying a prospective dividend yield of 4.5%.
Current consensus EPS estimate suggests the PER is 16.5.

Forecast for FY27:

Jarden forecasts a full year FY27 EPS of 23.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 15.38.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 24.0, implying annual growth of 8.6%.
Current consensus DPS estimate is 17.9, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 15.2.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

ELD    ELDERS LIMITED

Agriculture – Overnight Price: $7.34

Canaccord Genuity rates ((ELD)) as Buy (1) –

Elders’ investor day included trading commentary that was broadly in line with recent industry feedback, Canaccord Genuity notes, headlined by strong livestock prices and a continuation of challenging trading conditions for crop protection in SE Australia.

Beyond this, management articulated plans across multiple growth drivers. In Canaccord’s view, the potential contribution to medium-term earnings and cash flow from these initiatives is well in excess of the broker’s forecasts.

Specific and nearterm potential catalysts include Killara divestment and CEO succession. Target rises to $8.08 from $7.93, Buy retained.

This report was published on February 2, 2026.

Target price is $8.08 Current Price is $7.34 Difference: $0.74
If ELD meets the Canaccord Genuity target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $8.74, suggesting upside of 20.4%(ex-dividends)
The company’s fiscal year ends in September.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 36.00 cents and EPS of 52.00 cents.
At the last closing share price the estimated dividend yield is 4.90%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.12.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 59.5, implying annual growth of 118.6%.
Current consensus DPS estimate is 38.0, implying a prospective dividend yield of 5.2%.
Current consensus EPS estimate suggests the PER is 12.2.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 36.00 cents and EPS of 54.00 cents.
At the last closing share price the estimated dividend yield is 4.90%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.59.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 65.3, implying annual growth of 9.7%.
Current consensus DPS estimate is 40.3, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 11.1.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

EMR    EMERALD RESOURCES NL

Gold & Silver – Overnight Price: $6.84

Canaccord Genuity rates ((EMR)) as Downgrade to Hold from Buy (3) –

Canaccord Genuity has downgraded Emerald Resources to Hold from Buy on valuation grounds while lifting its target to $7.35 from $7.10 following the full December quarter report.

Gold production of 25koz missed the broker’s estimate, although costs were better than expected, supported by record recoveries, while cash and bullion rose to $370m with the company remaining debt free and unhedged.

FY26 guidance of 105–120koz at AISC of US$966/oz was reiterated, though Canaccord notes delivery of the midpoint requires a step up to record quarterly production levels in the second half.

This report was published on January 30, 2026.

Target price is $7.35 Current Price is $6.84 Difference: $0.51
If EMR meets the Canaccord Genuity target it will return approximately 7% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.43 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 1590.70.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.12 cents and EPS of 0.62 cents.
At the last closing share price the estimated dividend yield is 0.02%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 1103.23.

Market Sentiment: -1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

HRZ    HORIZON MINERALS LIMITED

Gold & Silver – Overnight Price: $1.36

Research as a Service (RaaS) rates ((HRZ)) as No Rating (-1) –

Horizon Minerals’ December quarter update missed Research as a Service’s (RaaS) expectations due to low mill throughput at Paddington.

Operations were broadly breakeven, with cash rising $3.1m on the back of the Lake Johnston sale, and a further $20m cash plus $5m in shares expected in the March 2026 quarter.

Boorara mining is complete, with the remaining ore to be processed in 1H2026 and expected to generate material cash flow, the analyst highlights. Phillips Find is nearing completion with total distributions to the company estimated at $14m.

Valuation trimmed to $3.62 from $3.675, reflecting updated Boorara and Phillips Find cash flows, delay to Black Swan refurbishment, and capital structure changes after Nebari loan conversion and share consolidation.

Research as a Service (RaaS) research doesn’t carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.

This report was published on February 2, 2026.

Target price is $3.62 Current Price is $1.36 Difference: $2.26
If HRZ meets the Research as a Service (RaaS) target it will return approximately 166% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Research as a Service (RaaS) forecasts a full year FY26 dividend of 0.00 cents and EPS of 17.38 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.83.

Forecast for FY27:

Research as a Service (RaaS) forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 2.86 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 47.55.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

ILU    ILUKA RESOURCES LIMITED

Mineral Sands – Overnight Price: $5.23

Canaccord Genuity rates ((ILU)) as Buy (1) –

Canaccord Genuity has lowered its target to $6.55 from $7.30 while retaining a Buy rating post the 4Q2025 results.

Mineral sands production and sales beat expectations but were offset by weaker average selling prices.

Production guidance for 2026 was set at 265kt and unit cash costs of $1,585/t, below consensus volumes, reflecting Cataby and SR2 remaining offline and higher costs from the Balranald ramp-up.

The broker sees no near-term recovery in mineral sands demand, particularly from China, but notes Balranald commissioning and Eneabba site works remain on track as key medium-term growth drivers. 

This report was published on January 30, 2026.

Target price is $6.55 Current Price is $5.23 Difference: $1.32
If ILU meets the Canaccord Genuity target it will return approximately 25% (excluding dividends, fees and charges).
Current consensus price target is $5.76, suggesting upside of 12.6%(ex-dividends)
The company’s fiscal year ends in December.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 EPS of minus 1.28 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 408.59.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 5.7, implying annual growth of -89.5%.
Current consensus DPS estimate is 5.6, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 89.6.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 EPS of minus 0.39 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 1341.03.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -6.8, implying annual growth of N/A.
Current consensus DPS estimate is 4.4, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is N/A.

Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

IPD    IMPEDIMED LIMITED

Medical Equipment & Devices – Overnight Price: $0.02

Canaccord Genuity rates ((IPD)) as Speculative Buy (1) –

Canaccord Genuity maintains a Speculative Buy rating on ImpediMed and lowers its target to 6c from 7c.

While the breast cancer-related lymphedema (BCRL) business possesses a better reimbursement set-up than most medtechs ever get to enjoy, commentary highlights growth remains a struggle.

ImpediMed is yet to mount the sales acceleration Canaccord assessed was due. This pressure on the short-term revenue outlook naturally draws the broker’s attention and focus to balance sheet risk.

Canaccord’s valuation only considers the BCRL opportunity in the US, which the broker believes is appropriate given the business is constrained from investing much outside lymphoedema.

This report was published on February 2, 2026.

Target price is $0.06 Current Price is $0.02 Difference: $0.04
If IPD meets the Canaccord Genuity target it will return approximately 200% (excluding dividends, fees and charges).
Current consensus price target is $0.09, suggesting upside of 341.7%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 2.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -0.9, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 2.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is -0.6, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

JIN    JUMBO INTERACTIVE LIMITED

Gaming – Overnight Price: $10.01

Jarden rates ((JIN)) as Buy (1) –

Ahead of Jumbo Interactive’s first half result, Jarden downgrades its FY26 earnings forecast by -4%, reflecting persistent weak jackpot activity through end-2025. The broker’s estimate sits in line with consensus.

Longer term, Jarden downgrades earnings circa -2% by FY28 on marginally more conservative digital penetration assumptions.

Target falls to $13.10 from $13.40, Overweight retained.

This report was published on January 30, 2026.

Target price is $13.10 Current Price is $10.01 Difference: $3.09
If JIN meets the Jarden target it will return approximately 31% (excluding dividends, fees and charges).
Current consensus price target is $13.33, suggesting upside of 33.7%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 32.00 cents and EPS of 78.00 cents.
At the last closing share price the estimated dividend yield is 3.20%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.83.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 76.5, implying annual growth of 19.3%.
Current consensus DPS estimate is 38.7, implying a prospective dividend yield of 3.9%.
Current consensus EPS estimate suggests the PER is 13.0.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 46.00 cents and EPS of 105.00 cents.
At the last closing share price the estimated dividend yield is 4.60%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.53.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 99.7, implying annual growth of 30.3%.
Current consensus DPS estimate is 48.6, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 10.0.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

KCN    KINGSGATE CONSOLIDATED LIMITED

Gold & Silver – Overnight Price: $5.69

Canaccord Genuity rates ((KCN)) as Buy (1) –

Kingsgate Consolidated’s balance sheet strength improved through the 2Q26 with cash and bullion rising to $179m and borrowings reduced to $15m post quarter end, notes Canaccord Genuity.

Production was pre-released and AISC tracked broadly in line despite lower grades, with operations still on course to meet guidance of 93–103koz AuEq at pre-royalty AISC of US$1,550–1,750/oz.

The broker expects grades and recoveries to improve into 2H26 as ore blending flexibility increases. Buy is retained and the target lifted to $9.30 from $8.35.

This report was published on January 30, 2026.

Target price is $9.30 Current Price is $5.69 Difference: $3.61
If KCN meets the Canaccord Genuity target it will return approximately 63% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 71.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.01.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 105.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5.42.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

KMD    KMD BRANDS LIMITED

Sports & Recreation – Overnight Price: $0.24

Jarden rates ((KMD)) as Overweight (2) –

Jarden note sales momentum across KMD Brands continued into the second quarter, and sales for the five months in the year to date are up 7.9%.

For Rip Curl North America the broker will look for more detail on the impact of tariffs on gross margins in that market at the half-year results.

Generally, gross margin is improving although remains suppressed, commentary highlights, and improvement is expected to be driven by a combination of mix, lower clearance and new products.

Jarden retains an Overweight rating with an NZ$0.45 target.

This report was published on February 2, 2026.

Current Price is $0.24. Target price not assessed.
The company’s fiscal year ends in July.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.54 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 44.44.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.52 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.53.

This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

LRK    LARK DISTILLING CO. LIMITED

Food, Beverages & Tobacco – Overnight Price: $0.61

Canaccord Genuity rates ((LRK)) as Speculative Buy (1) –

Six consecutive quarters of net sales growth were confirmed in Lark Distilling Co’s 2Q26 update, with revenue of $5.0m up 11% y/y and ahead of Canaccord Genuity expectations.

The broker highlights strong direct-to-consumer momentum alongside progress on export activations.

Direct Export and global travel retail continue to build from a low base, while softer domestic business-to-business reflected shipment timing rather than underlying demand.

Cash of $18.3m and no debt underpin execution of the re-staged brand strategy, with South East Asia distribution now complete and further market launches imminent.

Speculative Buy and $1.34 target are retained, with forecasts unchanged ahead of the 1H26 result.

This report was published on January 29, 2026.

Target price is $1.34 Current Price is $0.61 Difference: $0.73
If LRK meets the Canaccord Genuity target it will return approximately 120% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 6.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 10.17.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 4.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 15.25.

All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

LTR    LIONTOWN LIMITED

New Battery Elements – Overnight Price: $1.77

Canaccord Genuity rates ((LTR)) as Buy (1) –

Underground ramp-up momentum at Kathleen Valley drove a strong December quarter, with production of 105kt SC5.1 up 21% q/q and costs materially below expectations, notes Canaccord Genuity.

Lower realised pricing weighed on revenue and cash of $390m was slightly softer on working capital, with pro forma debt at circa $355m following the LG Energy Solution note conversion.

FY26 guidance of 365–450kt spodumene concentrate at AISCs of $1,060–1,295/t was reiterated and is viewed as readily achievable, with the broker forecasting positive free cash flow in 2H26 as underground feed increases.

Canaccord also flags renewed expansion optionality as lithium market deficits are projected to emerge from 2027. Buy and $2.40 target are unchanged

This report was published on January 29, 2026.

Target price is $2.40 Current Price is $1.77 Difference: $0.63
If LTR meets the Canaccord Genuity target it will return approximately 36% (excluding dividends, fees and charges).
Current consensus price target is $1.94, suggesting upside of 11.3%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 EPS of 0.03 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5900.00.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 1.1, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 158.2.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 EPS of 0.35 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 505.71.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 16.5, implying annual growth of 1400.0%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 10.5.

Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

NAB    NATIONAL AUSTRALIA BANK LIMITED

Banks – Overnight Price: $43.93

Jarden rates ((NAB)) as Sell (5) –

The December 2025 data showed mixed trends for major banks, with Westpac ((WBC)) and CommBank ((CBA)) gaining share in home loans. ANZ Bank ((ANZ)) and National Australia Bank lost momentum, and Macquarie Group ((MQG)) continued to take share from the majors, Jarden observes.

In corporate lending, Westpac showed strong gains and CommBank also improved, weakening National Australia Bank’s claim to sector leadership.

CommBank remained dominant in personal loans despite some slippage, while deposits saw CommBank gain, Westpac lose share, and Judo Capital ((JDO)) continue to deliver strong growth.

Sell rating for National Australia Bank, with target of $29.

This report was published on January 30, 2026.

Target price is $29.00 Current Price is $43.93 Difference: minus $14.93 (current price is over target).
If NAB meets the Jarden target it will return approximately minus 34% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $39.66, suggesting downside of -9.6%(ex-dividends)
The company’s fiscal year ends in September.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 171.00 cents and EPS of 227.00 cents.
At the last closing share price the estimated dividend yield is 3.89%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.35.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 237.1, implying annual growth of 7.3%.
Current consensus DPS estimate is 171.8, implying a prospective dividend yield of 3.9%.
Current consensus EPS estimate suggests the PER is 18.5.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 171.00 cents and EPS of 229.00 cents.
At the last closing share price the estimated dividend yield is 3.89%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.18.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 246.3, implying annual growth of 3.9%.
Current consensus DPS estimate is 169.6, implying a prospective dividend yield of 3.9%.
Current consensus EPS estimate suggests the PER is 17.8.

Market Sentiment: -0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

NEC    NINE ENTERTAINMENT CO. HOLDINGS LIMITED

Print, Radio & TV – Overnight Price: $1.21

Jarden rates ((NEC)) as Overweight (2) –

Nine Entertainment is repositioning its portfolio through the $850m acquisition of QMS Media and divestment of radio and regional TV assets, Jarden notes. 

The broker assesses the decision as strategically sound, repositioning the company toward higher-growth digital assets, with digital expected to exceed 60% of revenue by FY27.

The QMS price is reasonable in the broker’s view, with a forecast for over 10% pro forma EPS accretion by FY28, contingent on delivering $20m in cost synergies by FY29.

Leverage is set to rise before deleveraging through cash flow, though dividend risk remains in a material ad market downturn, the broker highlights.

Overweight rating and $1.25 target are unchanged.

This report was published on January 30, 2026.

Target price is $1.25 Current Price is $1.21 Difference: $0.04
If NEC meets the Jarden target it will return approximately 3% (excluding dividends, fees and charges).
Current consensus price target is $1.64, suggesting upside of 35.5%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 5.20 cents and EPS of 7.50 cents.
At the last closing share price the estimated dividend yield is 4.30%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.13.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 9.5, implying annual growth of 44.8%.
Current consensus DPS estimate is 6.7, implying a prospective dividend yield of 5.5%.
Current consensus EPS estimate suggests the PER is 12.7.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 6.30 cents and EPS of 9.00 cents.
At the last closing share price the estimated dividend yield is 5.21%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.44.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.6, implying annual growth of 22.1%.
Current consensus DPS estimate is 8.2, implying a prospective dividend yield of 6.8%.
Current consensus EPS estimate suggests the PER is 10.4.

Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

OBM    ORA BANDA MINING LIMITED

Gold & Silver – Overnight Price: $1.18

Canaccord Genuity rates ((OBM)) as Buy (1) –

Canaccord Genuity has lowered its target price to $1.60 from $1.70 and retained a Buy rating following a softer 2Q26 quarter.

Production of 32koz missed expectations and AISCs rose sharply to $3,505/oz on higher third-party milling costs and a low-grade sequence at Sand King.

FY26 production guidance of 140–155koz was retained, albeit skewed to the lower end, while AISC guidance was lifted materially to $3,250–3,350/oz on increased reliance on third-party processing in 2H FY26.

Growth capex guidance was raised to $143m to fund the new processing plant FEED study.

This report was published on January 30, 2026.

Target price is $1.60 Current Price is $1.18 Difference: $0.42
If OBM meets the Canaccord Genuity target it will return approximately 36% (excluding dividends, fees and charges).

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

ORG    ORIGIN ENERGY LIMITED

Infrastructure & Utilities – Overnight Price: $11.12

Jarden rates ((ORG)) as Neutral (3) –

Jarden describes Origin Energy’s December quarter update as in-line for APLNG with a cautious guidance upgrade, Energy Markets (EM) benefiting from a lower Eraring cost outlook, and Octopus Energy delivering strong organic customer growth.

Still, the broker cut FY26 EPS forecast by -6% on lower EM volumes, weaker Octopus EBITDA and reduced APLNG distributions. EBITDA for 1H26 is now forecast at $1,554m, a downgrade of -8%, due to greater 2H skew.

While valuation lifts on lower Eraring coal costs and reduced capex, the broker cautions a small 1H26 results miss could drive outsized share price volatility.

Neutral. Target rises to $11.65 from $11.60.

This report was published on January 30, 2026.

Target price is $11.65 Current Price is $11.12 Difference: $0.53
If ORG meets the Jarden target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $12.03, suggesting upside of 9.2%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 60.00 cents and EPS of 65.50 cents.
At the last closing share price the estimated dividend yield is 5.40%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.98.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 66.1, implying annual growth of -23.3%.
Current consensus DPS estimate is 60.8, implying a prospective dividend yield of 5.5%.
Current consensus EPS estimate suggests the PER is 16.7.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 60.00 cents and EPS of 58.30 cents.
At the last closing share price the estimated dividend yield is 5.40%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 19.07.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 58.2, implying annual growth of -12.0%.
Current consensus DPS estimate is 61.8, implying a prospective dividend yield of 5.6%.
Current consensus EPS estimate suggests the PER is 18.9.

Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PLS    PLS GROUP LIMITED

New Battery Elements – Overnight Price: $4.33

Jarden rates ((PLS)) as Neutral (3) –

PLS Group will consider the restart of Ngungaju in the current quarter. The 200,000tpa concentrator was idled in December 2024. Jarden expects first production in early FY27, estimating that up to around 12% of global supply is currently idle and a further 3-4% constrained by geopolitics.

The broker retains a view that the current lithium prices will reduce the imminent return of idle capacity and put a ceiling on the price rally. 

PLS Group’s balance sheet retains a key strategic advantage versus the majority of its peers which are significantly geared. Neutral rating. Target rises to $2.50 from $2.40.

This report was published on January 31, 2026.

Target price is $2.50 Current Price is $4.33 Difference: minus $1.83 (current price is over target).
If PLS meets the Jarden target it will return approximately minus 42% (excluding dividends, fees and charges – negative figures indicate an expected loss).
Current consensus price target is $4.81, suggesting upside of 12.2%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 11.90 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 36.39.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 10.7, implying annual growth of N/A.
Current consensus DPS estimate is 0.8, implying a prospective dividend yield of 0.2%.
Current consensus EPS estimate suggests the PER is 40.1.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 8.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 52.17.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 24.8, implying annual growth of 131.8%.
Current consensus DPS estimate is 4.6, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 17.3.

Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

PXA    PEXA GROUP LIMITED

Real Estate – Overnight Price: $13.25

Jarden rates ((PXA)) as Buy (1) –

Jarden remains cautiously optimistic regarding the outcome of Australian regulatory reviews, suspecting the status quo will be maintained in terms of electronic conveyancing and the IPART pricing review.

The broker retains a view that any Australian regulatory downside risk is more than offset by UK upside and retains a Buy rating for Pexa Group.

Scenario analysis signals around 17% terminal EBITDA upside if the status quo continues and the company attains 95% terminal market share. Target is $17.40.

This report was published on February 1, 2026.

Target price is $17.40 Current Price is $13.25 Difference: $4.15
If PXA meets the Jarden target it will return approximately 31% (excluding dividends, fees and charges).
Current consensus price target is $17.40, suggesting upside of 28.6%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 29.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 45.07.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 20.5, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 66.0.

Forecast for FY27:

Jarden forecasts a full year FY27 EPS of 42.60 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 31.10.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 28.7, implying annual growth of 40.0%.
Current consensus DPS estimate is 5.7, implying a prospective dividend yield of 0.4%.
Current consensus EPS estimate suggests the PER is 47.1.

Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

REG    REGIS HEALTHCARE LIMITED

Aged Care & Seniors – Overnight Price: $6.70

Jarden rates ((REG)) as Overweight (2) –

Ahead of the first half results for Regis Healthcare on February 23, Jarden forecasts EBITDA of $65.9m. This would be down -3%  comparatively.

The forecast decline is largely stemming from the cycling of a strong second quarter in FY25 where a “one-off profit” of $5m was recorded stemming from government funding.

The broker considers the ongoing review into the accommodation supplement as a major opportunity for the business in the next six months, with the most likely outcome to be a $10-20 increase per resident per day.

Overweight rating. Target is reduced to $8.30 from $8.40.

This report was published on February 2, 2026.

Target price is $8.30 Current Price is $6.70 Difference: $1.6
If REG meets the Jarden target it will return approximately 24% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 13.80 cents and EPS of 19.70 cents.
At the last closing share price the estimated dividend yield is 2.06%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 34.01.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 18.20 cents and EPS of 26.40 cents.
At the last closing share price the estimated dividend yield is 2.72%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 25.38.

Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

RMD    RESMED INC

Medical Equipment & Devices – Overnight Price: $35.71

Canaccord Genuity rates ((RMD)) as Buy (1) –

If there’s a new structural theme to re-rate ResMed in a durable way, Canaccord Genuity believes it has to come from owning and controlling diagnostic and referral infrastructure tailored to tech-generated and GLP-1-associated demand.

The broker maintains a Buy rating on ResMed with a reduced price target of $46.50 down from $50.00. Notwithstanding consistent beats, including Dec Q earnings 3% ahead of forecast, and an impressive set of sector tailwinds forming, the stock tracks sideways.

The FDA’s approval of Novo Nordisk’s first-in-class oral GLP-1 Wegovy tablet for weight management materially broadens the treated pool, Canaccord notes.

This report was published on February 2, 2026.

Target price is $46.50 Current Price is $35.71 Difference: $10.79
If RMD meets the Canaccord Genuity target it will return approximately 30% (excluding dividends, fees and charges).
Current consensus price target is $47.23, suggesting upside of 26.1%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 37.69 cents and EPS of 170.15 cents.
At the last closing share price the estimated dividend yield is 1.06%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.99.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 158.9, implying annual growth of N/A.
Current consensus DPS estimate is 35.4, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 23.6.

Forecast for FY27:

Canaccord Genuity forecasts a full year FY27 dividend of 40.31 cents and EPS of 188.31 cents.
At the last closing share price the estimated dividend yield is 1.13%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.96.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 178.0, implying annual growth of 12.0%.
Current consensus DPS estimate is 39.5, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 21.1.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

Jarden rates ((RMD)) as Overweight (2) –

The second quarter delivered 15% net profit growth for ResMed with Jarden assessing results were strong across most metrics.

Double-digit earnings growth and strong cash flow pushed the balance sheet into a US$753m net cash position.

The broker considers the stock cheap while earnings growth is expected to stay in double digits for at least the next three years. Overweight rating. Target rises to $45.20  from $45.10.

This report was published on January 30, 2026.

Target price is $45.20 Current Price is $35.71 Difference: $9.49
If RMD meets the Jarden target it will return approximately 27% (excluding dividends, fees and charges).
Current consensus price target is $47.23, suggesting upside of 26.1%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 EPS of 173.23 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.61.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 158.9, implying annual growth of N/A.
Current consensus DPS estimate is 35.4, implying a prospective dividend yield of 0.9%.
Current consensus EPS estimate suggests the PER is 23.6.

Forecast for FY27:

Jarden forecasts a full year FY27 EPS of 198.31 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 18.01.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 178.0, implying annual growth of 12.0%.
Current consensus DPS estimate is 39.5, implying a prospective dividend yield of 1.1%.
Current consensus EPS estimate suggests the PER is 21.1.

This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

TPW    TEMPLE & WEBSTER GROUP LIMITED

Furniture & Renovation – Overnight Price: $11.67

Jarden rates ((TPW)) as Buy (1) –

Jarden is more cautious on discretionary stocks on higher interest rate prospects, though reckons much of this is priced in, particularly across household goods.

The broker continues to favour names with structural tailwinds like Breville Group ((BRG)) and Sigma Healthcare ((SIG)), and share gains like Temple & Webster while remaining cautious on more cyclical stocks.

Buy rating and $19.90 target for Temple & Webster.

This report was published on January 30, 2026.

Target price is $19.90 Current Price is $11.67 Difference: $8.23
If TPW meets the Jarden target it will return approximately 71% (excluding dividends, fees and charges).
Current consensus price target is $20.37, suggesting upside of 74.4%(ex-dividends)
The company’s fiscal year ends in June.

Forecast for FY26:

Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 11.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 98.90.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 11.3, implying annual growth of 18.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 103.4.

Forecast for FY27:

Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 19.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 60.15.

How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 21.3, implying annual growth of 88.5%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 54.8.

Market Sentiment: 0.6
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

WAF    WEST AFRICAN RESOURCES LIMITED

Gold & Silver – Overnight Price: $3.49

Canaccord Genuity rates ((WAF)) as Speculative Buy (1) –

Canaccord Genuity removes West African Resources from Under Review and initiates a Speculative Buy with a $5.70 target following a strong December quarter and 2025 production beat of 300koz at AISC of US$1,488/oz, ahead of broker expectations.

The result was driven by a faster-than-anticipated ramp-up at Kiaka, where production of 62koz materially exceeded forecasts, while Sanbrado delivered broadly in line despite a planned shutdown.

Net cash stood at US$204m at quarter end, providing balance sheet strength as Kiaka continues to ramp, albeit with power reliability and cost pressures flagged as ongoing risks.

For 2026, Canaccord models group production of 479koz at AISC of US$1,652/oz, noting higher gold prices are likely to lift royalties and costs.

This report was published on January 30, 2026.

Target price is $5.70 Current Price is $3.49 Difference: $2.21
If WAF meets the Canaccord Genuity target it will return approximately 63% (excluding dividends, fees and charges).
The company’s fiscal year ends in December.

Forecast for FY25:

Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of 47.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 7.43.

Forecast for FY26:

Canaccord Genuity forecasts a full year FY26 dividend of 19.00 cents and EPS of 97.00 cents.
At the last closing share price the estimated dividend yield is 5.44%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 3.60.

Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources

Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.

This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.

<span style="

Click to view our Glossary of Financial Terms